Day: August 18, 2020

VANCOUVER, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX-V: KNT; OTCQX: KNTNF) announces the grant of 550,000 incentive stock options (the “Stock Options”) to a director of the Company, under its incentive stock option plan (the “Plan”). The Stock Options have an exercise price of $7.25 per share, expire five years from the date of grant, and will vest periodically over the next 12 months in accordance with the Plan. The Stock Options are subject to a trading hold period expiring four months plus one day from the date of grant.On Behalf of the Company,John Lewins, Chief Executive Officer and DirectorFor further information, please contact David Medilek, P.Eng., CFA at +1-604-687-7130.NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES...

TORONTO, Aug. 17, 2020 (GLOBE NEWSWIRE) — Caldas Gold Corp. (TSX-V: CGC; OTCQX: ALLXF) announced today that it has filed a preliminary feasibility study (“PFS”) technical report on its Marmato Project (the “Technical Report”) pursuant to National Instrument 43‐101 – Standards of Disclosure for Mineral Projects (“NI 43‐101″). The Technical Report supports the disclosure made by the Company in its July 6, 2020 news release and is based on the updated Mineral Resource and Mineral Reserve estimates for the Marmato Project with an effective date of March 17, 2020.A summary of the key life-of-mine operating and financial results in the Technical Report compared with the preliminary results announced by the Company on July 6, 2020 is as follows:The Technical Report, with a report date of August 17, 2020 and an effective date...

BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that further to its news release dated August 11, 2020, it has received the approval of the TSX Venture Exchange for the shares for debt transaction, to settle the aggregate of $374,000 in indebtness of the Company, through the issuance of 50,000 common shares of the Company (each, a “Share“) at a deemed price of $7.48 per Share (“Debt Settlement“).All securities issued pursuant to the Debt Settlement are subject to a hold period of four-months and one day.About BriaCellBriaCell is an immuno-oncology focused...

BATON ROUGE, La., Aug. 17, 2020 (GLOBE NEWSWIRE) — Lamar Advertising Company (Nasdaq: LAMR) announced today that its wholly owned subsidiary, Lamar Media Corp (“Lamar Media”), has agreed to sell $150.0 million of additional 4% Senior Notes due 2030 (the “Notes”) through an institutional private placement. The Notes are being issued as additional notes to the existing $400.0 million aggregate principal amount of ‎4% Senior Notes due 2030 that Lamar Media issued on February 6, 2020 (the “Existing Notes”). Other than with respect to the date of issuance and issue price, the Notes will have the same terms as the Existing Notes.‎ The Notes will be maintained under the same CUSIP numbers as the Existing Notes (except that the Notes ‎issued pursuant to Regulation S will trade separately under a different CUSIP number until 40 days after...

TOKYO, Aug. 18, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Japan.The objective of the study, termed the “ZIRDAC-JP” (Zirconium Dosing and Comparison in Japan) study is to confirm the safety and tolerability, as well as sensitivity and specificity of positron emission tomography (PET) imaging with TLX250-CDx to detect clear cell renal cell cancer (ccRCC) in Japanese patients. The patient population for the ZIRDAC-JP trial has been selected to be identical to the global Phase III ZIRCON trial, with comparison to surgical resection (histology) as standard of truth....